Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis Copen access
- Authors
- Kwon, J.H.[Kwon, J.H.]; Bae, S.H.[ Bae, S.H.]; Choi, J.Y.[ Choi, J.Y.]; Yoon, S.K.[ Yoon, S.K.]; Byun, K.S.[ Byun, K.S.]; Paik, S.W.[Paik, S.W.]; Lim, Y.S.[ Lim, Y.S.]; Lee, H.C.[ Lee, H.C.]; Han, K.H.[ Han, K.H.]; Lee, K.S.[ Lee, K.S.]
- Issue Date
- 2009
- Keywords
- Hepatitis C; Koreans; Peginterferon alfa-2a; Ribavirin
- Citation
- Korean Journal of Internal Medicine, v.24, no.3, pp.203 - 211
- Indexed
- SCOPUS
KCI
- Journal Title
- Korean Journal of Internal Medicine
- Volume
- 24
- Number
- 3
- Start Page
- 203
- End Page
- 211
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/79189
- DOI
- 10.3904/kjim.2009.24.3.203
- ISSN
- 1226-3303
- Abstract
- Background/Aims: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginterferon α-2a and ribavirin dose modifications and their effect on the virologic response in Koreans. Methods: Patients with detectable HCV RNA and enrolled from multicenters were treated with peginterferon α-2a (180 μg/week) and ribavirin (800 mg/day) for 24 weeks (genotype non-1, n=37) or peginterferon α-2a (180 μg/ week) and ribavirin (1,000-1,200 mg/day) for 48 weeks (genotype 1, n=55). Results: Early virologic response (EVR) and sustained virologic response (SVR) were 77.2% (genotype 1, 75%; non-1, 81%) and 66.3% (genotype 1, 56%; non-1, 81%), respectively. The frequency of dose modification was 32.6% within the first 12 weeks and 52.2% during the entire treatment period. No difference was found in SVR regardless of dose modification. However, the SVR for patients using ≥80% of the peginterferon dose was significantly higher than for those using <80% (81.3 vs. 50.0%, p=0.007), despite varying ribavirin doses. No difference was found in SVR regardless of whether the ribavirin dose was <80% or not. These results did not change based on genotype. Conclusions: We suggest that using at least 80% of the peginterferon α-2a dose in Koreans not only maintains SVR but also reduces drug side effects during the entire treatment period. A lower dose of ribavirin may be as efficacious as a standard dose.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/79189)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.